Ruohui Zheng1, Lingxiao Pan2, Jin Gao2, Xigang Ye2, Lun Chen2, Xiaoshen Zhang2, Wei Tang3, Wenbo Zheng4. 1. Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; Department of Biotechnology, School of Life Science, Sun Yat-Sen University, Guangzhou, People's Republic of China. 2. Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China. 3. Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China. Electronic address: wayetom@163.com. 4. Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China. Electronic address: wenbo_zheng@163.com.
Abstract
BACKGROUND: The aim of the present study was to evaluate whether the level of expression of tissue or plasma miR-106b can be used to predict clinical outcomes in breast cancer patients. METHODS: Both tissue and plasma samples were collected and analyzed from 173 patients with primary breast cancer and a set of 50 women with fibroadenoma. The relative expression levels of miR-106b were determined using real-time quantitative reverse transcription polymerase chain reaction and in situ hybridization. RESULTS: The levels of miR-106b were upregulated in both tissue and plasma samples from breast cancer patients. The expression levels showed a linear correlation (rs = 0.748, P < 0.001) and were significantly correlated with tumor size, Ki67 expression, and lymph node metastasis (all P < 0.05). Patients with high miR-106b expression levels tended to have shorter disease-free survival times and overall survival times (P < 0.001). In a Cox regression model, high-level tissue and plasma miR-106b expression were unfavorable prognostic factors, and receiver-operating characteristic analysis revealed that the tissue and plasma miR-106b levels provided considerable diagnostic accuracy, yielding an area under the ROC curve of 0.785 and 0.856, respectively. CONCLUSIONS: MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer.
BACKGROUND: The aim of the present study was to evaluate whether the level of expression of tissue or plasma miR-106b can be used to predict clinical outcomes in breast cancerpatients. METHODS: Both tissue and plasma samples were collected and analyzed from 173 patients with primary breast cancer and a set of 50 women with fibroadenoma. The relative expression levels of miR-106b were determined using real-time quantitative reverse transcription polymerase chain reaction and in situ hybridization. RESULTS: The levels of miR-106b were upregulated in both tissue and plasma samples from breast cancerpatients. The expression levels showed a linear correlation (rs = 0.748, P < 0.001) and were significantly correlated with tumor size, Ki67 expression, and lymph node metastasis (all P < 0.05). Patients with high miR-106b expression levels tended to have shorter disease-free survival times and overall survival times (P < 0.001). In a Cox regression model, high-level tissue and plasma miR-106b expression were unfavorable prognostic factors, and receiver-operating characteristic analysis revealed that the tissue and plasma miR-106b levels provided considerable diagnostic accuracy, yielding an area under the ROC curve of 0.785 and 0.856, respectively. CONCLUSIONS:MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer.
Authors: Nicole Ludwig; Anne Hecksteden; Mustafa Kahraman; Tobias Fehlmann; Thomas Laufer; Fabian Kern; Tim Meyer; Eckart Meese; Andreas Keller; Christina Backes Journal: RNA Biol Date: 2019-05-10 Impact factor: 4.652